PE20110106A1 - Peptidos mediadores del eflujo del colesterol mejorados - Google Patents
Peptidos mediadores del eflujo del colesterol mejoradosInfo
- Publication number
- PE20110106A1 PE20110106A1 PE2010001150A PE2010001150A PE20110106A1 PE 20110106 A1 PE20110106 A1 PE 20110106A1 PE 2010001150 A PE2010001150 A PE 2010001150A PE 2010001150 A PE2010001150 A PE 2010001150A PE 20110106 A1 PE20110106 A1 PE 20110106A1
- Authority
- PE
- Peru
- Prior art keywords
- cholesterol efflux
- mediator
- peptides
- polypeptide
- refers
- Prior art date
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 235000012000 cholesterol Nutrition 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 3
- DHMQDGOQFOQNFH-CNRUNOGKSA-N 2-amino-2-tritioacetic acid Chemical compound [3H]C(N)C(O)=O DHMQDGOQFOQNFH-CNRUNOGKSA-N 0.000 abstract 1
- 241000670727 Amida Species 0.000 abstract 1
- 239000004475 Arginine Substances 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical group C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical group CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract 1
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 abstract 1
- 235000004279 alanine Nutrition 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 229940024606 amino acid Drugs 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 229940009098 aspartate Drugs 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229930195712 glutamate Natural products 0.000 abstract 1
- 229960000310 isoleucine Drugs 0.000 abstract 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UN POLIPEPTIDO QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS X1X2X3X4X5X6X7X8X9X10X11X12X13X14X15X16X17X18X19X20 (SEQ ID NO: 1) DONDE X1, X7 Y X15 SON CADA UNO E O D; X4, X11 Y X18 SON CADA UNO E, D, A O G; X2, X6, X9, X10, X12, X13, X16, X17 Y X20 SON CADA UNO F, L, W, I, V O A; X3, X5 Y X19 SON CADA UNO R, K O C; X14 ES R, A, E O C; Y X8 ES A, G O V, EN DONDE A ES ALANINA, C ES CISTEINA, D ES ASPARTATO, E ES GLUTAMATO, F ES FENILALANINA, G ES GLICINA, I ES ISOLEUCINA, K ES LISINA, L ES LEUCINA, R ES ARGININA, V ES VALINA, W ES TRIPTOFANO. ADEMAS EL POLIPEPTIDO COMPRENDE UN GRUPO PROTECTOR TAL COMO ACETILO, AMIDA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHO POLIPEPTIDO TIENE ACTIVIDAD DE EFLUJO DE COLESTEROL, INDUCE LA FORMACION DE PRE-BETA EN PLASMA, PROTEGE LA OXIDACION DE FOSFOLIPIDOS, ENTRE OTROS, SIENDO UTIL EN EL TRATAMIENTO DE LA ATEROSCLEROSIS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7370808P | 2008-06-18 | 2008-06-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20110106A1 true PE20110106A1 (es) | 2011-03-02 |
Family
ID=41434685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2010001150A PE20110106A1 (es) | 2008-06-18 | 2009-06-17 | Peptidos mediadores del eflujo del colesterol mejorados |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8415293B2 (es) |
| EP (1) | EP2300038A4 (es) |
| JP (1) | JP2011525181A (es) |
| KR (1) | KR20110043597A (es) |
| CN (1) | CN102123722A (es) |
| AU (1) | AU2009260024A1 (es) |
| BR (1) | BRPI0915422A2 (es) |
| CA (1) | CA2727465A1 (es) |
| CL (1) | CL2010001445A1 (es) |
| IL (1) | IL209868A0 (es) |
| MX (1) | MX2010014003A (es) |
| PE (1) | PE20110106A1 (es) |
| RU (1) | RU2011101536A (es) |
| WO (1) | WO2009155366A2 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130123173A1 (en) * | 2010-04-28 | 2013-05-16 | The Regents Of The University Of California | Creation of oxidation-resistant hdl mimetic peptides |
| EP2983687B1 (en) | 2013-03-15 | 2019-09-04 | The Regents of The University of California | Peptides having reduced toxicity that stimulate cholesterol efflux |
| CN106488987A (zh) | 2014-05-02 | 2017-03-08 | 塞勒尼斯医疗控股公司 | Hdl疗法标志物 |
| WO2016044177A1 (en) * | 2014-09-17 | 2016-03-24 | The Regents Of The University Of California | Peptides having reduced toxicity that stimulate cholesterol efflux |
| WO2017011312A1 (en) * | 2015-07-10 | 2017-01-19 | Peptinovo Biopharma, Llc | Formulations for improving the efficacy of hydrophobic drugs |
| EP3464613A4 (en) | 2016-05-31 | 2020-01-08 | Institut de Cardiologie de Montréal | CO-CULTURE SYSTEM AND METHOD FOR IN-VITRO EVALUATION OF CHOLESTERIN RETURN |
| CN110294791B (zh) * | 2019-06-13 | 2023-02-21 | 倪京满 | 具有胆固醇外流活性的抗动脉粥样硬化肽类似物及其应用 |
| CN111848742B (zh) * | 2020-07-23 | 2021-03-23 | 南京医科大学 | 一种多肽及其制药用途 |
| CN112511569B (zh) * | 2021-02-07 | 2021-05-11 | 杭州筋斗腾云科技有限公司 | 网络资源访问请求的处理方法、系统及计算机设备 |
| CN115300609A (zh) * | 2021-05-08 | 2022-11-08 | 西湖大学 | 缺氧诱导脂滴相关蛋白(hilpda)在预防或治疗高血脂相关疾病中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2549529A1 (en) | 2003-12-15 | 2005-06-30 | The Regents Of The University Of California | Helical synthetic peptides that stimulate cellular cholesterol efflux |
| ES2377329T3 (es) | 2006-12-13 | 2012-03-26 | The Regents Of The University Of California | Mediadores selectivos y potentes del flujo de salida de colesterol |
-
2009
- 2009-06-17 JP JP2011514778A patent/JP2011525181A/ja not_active Withdrawn
- 2009-06-17 RU RU2011101536/15A patent/RU2011101536A/ru not_active Application Discontinuation
- 2009-06-17 EP EP09767675.3A patent/EP2300038A4/en not_active Withdrawn
- 2009-06-17 MX MX2010014003A patent/MX2010014003A/es not_active Application Discontinuation
- 2009-06-17 CN CN2009801324185A patent/CN102123722A/zh active Pending
- 2009-06-17 KR KR1020117001120A patent/KR20110043597A/ko not_active Withdrawn
- 2009-06-17 PE PE2010001150A patent/PE20110106A1/es not_active Application Discontinuation
- 2009-06-17 WO PCT/US2009/047694 patent/WO2009155366A2/en not_active Ceased
- 2009-06-17 BR BRPI0915422A patent/BRPI0915422A2/pt not_active IP Right Cessation
- 2009-06-17 CA CA2727465A patent/CA2727465A1/en not_active Abandoned
- 2009-06-17 AU AU2009260024A patent/AU2009260024A1/en not_active Abandoned
- 2009-06-17 US US12/999,966 patent/US8415293B2/en active Active
-
2010
- 2010-12-09 IL IL209868A patent/IL209868A0/en unknown
- 2010-12-16 CL CL2010001445A patent/CL2010001445A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2011101536A (ru) | 2012-07-27 |
| WO2009155366A3 (en) | 2010-04-22 |
| US20110190196A1 (en) | 2011-08-04 |
| AU2009260024A1 (en) | 2009-12-23 |
| EP2300038A4 (en) | 2013-09-04 |
| EP2300038A2 (en) | 2011-03-30 |
| CL2010001445A1 (es) | 2012-03-16 |
| IL209868A0 (en) | 2011-02-28 |
| CN102123722A (zh) | 2011-07-13 |
| JP2011525181A (ja) | 2011-09-15 |
| MX2010014003A (es) | 2011-02-15 |
| US8415293B2 (en) | 2013-04-09 |
| KR20110043597A (ko) | 2011-04-27 |
| CA2727465A1 (en) | 2009-12-23 |
| WO2009155366A2 (en) | 2009-12-23 |
| BRPI0915422A2 (pt) | 2017-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20110106A1 (es) | Peptidos mediadores del eflujo del colesterol mejorados | |
| PE20110891A1 (es) | Vacuna de peptido ch3 de ige | |
| AR082805A1 (es) | PEPTIDO O COMPLEJO PEPTIDICO QUE SE UNE A INTEGRINA a2 Y METODOS Y USOS QUE IMPLICAN A LOS MISMOS | |
| EA033386B1 (ru) | Рекомбинантные иммуногенные полипептиды стеблевого домена гемагглютинина вируса гриппа а и их применение | |
| PE20121033A1 (es) | Produccion recombinante de peptidos | |
| PE20120358A1 (es) | Mutantes fgf21 y usos de los mismos | |
| ES2673556T3 (es) | Vacunas para el VHS-2 | |
| PE20121393A1 (es) | Analogo peptidico de oxintomodulina | |
| NZ598834A (en) | Prevention, treatment and diagnosis of P. gingivalis infection | |
| PE20121544A1 (es) | Vacuna de pcsk9 | |
| PE20141727A1 (es) | Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas | |
| PE20110394A1 (es) | Virus sincitial respiratorio vivo atenuado | |
| NZ598356A (en) | Antigenic tau peptides and uses thereof | |
| PE20130648A1 (es) | Tratamiento del sindrome de sanfilippo tipo b | |
| PE20081723A1 (es) | Vacuna contra el papilomavirus | |
| MX336715B (es) | Purificacion de iduronato-2-sulfatasa. | |
| EA202090053A2 (ru) | Способы и композиции для лечения неэффективного эритропоэза | |
| MX358725B (es) | Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden. | |
| JP2012115277A5 (es) | ||
| PE20140617A1 (es) | Alfa glucosidasa acida modificada con procesamiento acelerado | |
| PE20140190A1 (es) | Moduladores de proteinas notum y metodos de uso | |
| PE20090483A1 (es) | Vectores para la expresion multiple de genes | |
| CO6260151A2 (es) | Peptido de cdh3 y agente medicinal que comprende al mismo | |
| MX388822B (es) | Composiciones que comprenden peptido wkdeagkplvk. | |
| AR128395A2 (es) | Péptidos novedosos capaces de inducir la formación de anticuerpos contra pcsk9 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |